[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561720":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":29,"collaborators":25,"id":33,"slug":25,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":25,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":25,"overallStatus":52,"whyStopped":25,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":25},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","bacillus coagulans combined with the best treatment options for preventing aGVHD",[13],"Drug: bacillus coagulans combined with the best treatment options for preventing aGVHD",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","ACTIVE_COMPARATOR","The best treatment options for preventing aGVHD",[19],"Drug: BAT",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","BAT means the best treatment options for preventing aGVHD",[9],null,{"type":22,"name":27,"description":27,"armGroupLabels":28,"otherNames":25},"BAT",[15],{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Yamin Fan","Principal Investigator","100561720",false,"NCT06593834","A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation","A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease (aGVHD) After Hematopoietic Stem Cell Transplantation","aGVHD；BAT","Inclusion Criteria:\n\n1. Patients are fully aware of the study, voluntarily participate and sign informed consent;\n2. Age: ≥18 years old;\n3. Patients with hematologic malignancies undergoing allo-HSCT and patients with severe aplastic anemia (SAA) undergoing allo-HSCT were treated with myeloablative conditioning (MAC).\n\nExclusion Criteria:\n\n1. Refused to participate in this clinical study;\n2. Unable to take the drug orally;\n3. Allergic to Bacillus coagulans;\n4. People take allo-HSCT with reduced intensity conditioning (RIC) and nonmyeloablative conditioning (NMC);lymphoma or multiple myeloma with auto-HSCT; multiple myeloma patients.","ALL","18 Years","80 Years",{"count":44,"type":45},286,"ESTIMATED","INTERVENTIONAL",[48],"NA","To evaluate the preventive effect of Bacillus coagulans on acute graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation",[51],"Acute Graft-versus-host Disease","NOT_YET_RECRUITING","2024-09-22",{"date":55,"type":56},"2024-09-25","ACTUAL",{"date":58,"type":45},"2024-09-27",{"date":60,"type":45},"2026-04-30",{"name":31,"class":6}]